Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

被引：11
|
作者：
Sternberg, Cora N.
De Bono, Johann Sebastian
Chi, Kim N.
Fizazi, Karim
Mulders, Peter
Hirmand, Mohammad
Forer, David
Scher, Howard I.
机构：
[1] San Camillo & Forlanini Hosp, Rome, Italy
[2] Inst Canc Res, Sutton, Surrey, England
[3] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[4] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[5] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[6] Medivation Inc, San Francisco, CA USA
[7] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [32] PHASE 2 TRIAL OF A DNA VACCINE WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    McNeel, Douglas
    Eickhoff, Jens
    Wargowski, Ellen
    Johnson, Laura
    Kyriakopoulos, Christos
    Emamekhoo, Hamid
    Lang, Joshua
    Brennan, Mary Jane
    Liu, Glenn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A377 - A377
  • [33] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [34] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [35] Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
    Paredero Perez, I.
    Arnal, M.
    Lorente, D.
    Girones Sarrio, R.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Llacer Perez, C.
    Castro Marcos, E.
    Olmos, D.
    Sanchez Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S526 - S526
  • [36] Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.
    Naik, Gurudatta
    Bae, Sejong
    De Shazo, Mollie R.
    Dixon, Pam
    Merritt, Lynn
    Sartor, A. Oliver
    Schnell, Frederick M.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies.
    Mellgard, George Slade
    Chakrani, Zakaria
    Mccroskery, Stephen
    Saffran, Nathaniel
    Taylor, Nicole
    Liaw, Bobby Chi-Hung
    Galsky, Matt D.
    Oh, William K.
    Tsao, Kai
    Patel, Vaibhav G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
    Serritella, Anthony, V
    Shevrin, Daniel
    Heath, Elisabeth, I
    Wade, James L.
    Martinez, Elia
    Anderson, Amanda
    Schonhoft, Joseph
    Chu, Yen-Lin
    Karrison, Theodore
    Stadler, Walter M.
    Szmulewitz, Russell Z.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1549 - 1559
  • [39] Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Han, Xin
    Zhao, Lijie
    Xiang, Weiguo
    Qin, Chong
    Miao, Bukeyan
    Xu, Tianfeng
    Lu, Jianfeng
    Wang, Mi
    Wang, Shaomeng
    CANCER RESEARCH, 2020, 80 (16)
  • [40] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    Graff, Julie Nicole
    Cheng, Heather H.
    Vuky, Jacqueline
    Alumkal, Joshi J.
    Kreitner, Dustin
    Petreaca, Delia
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Chen, Yiyi
    Yu, Evan Y.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345